Clinical Trials Logo

Clinical Trial Summary

This is a randomized, double-blind, placebo-controlled, parallel-group study of armodafinil and placebo treatment in healthy subjects with excessive sleepiness associated with jet lag disorder.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00758498
Study type Interventional
Source Teva Pharmaceutical Industries
Contact
Status Completed
Phase Phase 3
Start date September 2008
Completion date February 2009

See also
  Status Clinical Trial Phase
Recruiting NCT01766323 - Palliative Morphine With or Without Concurrent Modafinil Phase 3
Completed NCT00711516 - Study to Evaluate Armodafinil Treatment in Improving Prefrontal Cortical Activation and Working Memory Performance Phase 4
Completed NCT00174174 - Provigil (Modafinil) Study by Taiwan Biotech Co. N/A
Terminated NCT04618263 - Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers Phase 1
Completed NCT01080807 - Efficacy and Tolerability of Armodafinil in Adults With Excessive Sleepiness Associated With Shift Work Disorder Phase 4
Completed NCT00080288 - Safety/Efficacy Study With Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Chronic SWSD Phase 3
Completed NCT02806908 - Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in Narcolepsy Phase 2
Completed NCT02806895 - Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in OSA Phase 2
Recruiting NCT04788953 - Clinical Trial of Solriamfetol for Excessive Sleepiness Related to Shift Work Disorder Phase 4
Completed NCT03881852 - Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT) Phase 2
Completed NCT03037203 - A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness Phase 2
Completed NCT05008341 - Evaluate Sunosi® PK in Breast Milk and Plasma of Healthy Postpartum Women Following Single Dose Oral Administration Phase 1